1. Generics Bulletin
  2. >>Products

FDA Releases Latest Product-Specific Guidances

Of 36 PSGs, 22 Are New And 14 Newly-Revised

 
• By Dave Wallace

The latest tranche of product-specific guidances for generic development has been published by the US FDA.

Number 36 House Sign
The FDA has published 36 new or newly-revised product-specific guidances • Source: Shutterstock

The US Food and Drug Administration has published its latest batch of product-specific guidances for generic drug development, with the 36 newly-released documents comprising 22 new guidances and 14 newly-revised PSGs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.